Evidence map›Paper›PMID 42359357›Full record

ReviewCell insight2026

Innate immune crosstalk in ALS/FTD pathogenesis.

Xiaoqiu Shu, Xinyuan Yu, Pinglong Xu, Ailian Wang

Abstract readReview
In one paragraph

Review in Cell insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiaoqiu ShuSir Run Run Shaw Hospital, Zhejiang University School of Medicine, and Life Sciences Institute, Zhejiang University, Hangzhou, 310058, China.
Xinyuan YuSir Run Run Shaw Hospital, Zhejiang University School of Medicine, and Life Sciences Institute, Zhejiang University, Hangzhou, 310058, China.
Pinglong XuSir Run Run Shaw Hospital, Zhejiang University School of Medicine, and Life Sciences Institute, Zhejiang University, Hangzhou, 310058, China.
Ailian WangSir Run Run Shaw Hospital, Zhejiang University School of Medicine, and Life Sciences Institute, Zhejiang University, Hangzhou, 310058, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Marked by protein aggregation, impaired proteostasis, organelle stress, and chronic neuroinflammation, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) form a clinically, genetically, and pathologically overlapping disease spectrum. Increasing evidence indicates that innate immune activation is not merely a secondary response to neuronal injury, but an active driver of disease progression. In this review, we elaborate on how ALS/FTD-associated genetic lesions and pathogenic protein aggregates, including TDP-43, SOD1, FUS, and C9orf72-derived dipeptide repeat proteins, engage three interconnected innate immune pathways: cGAS-STING, NLRP3 inflammasomes, and TREM2-DAP12 signaling. We further highlight emerging crosstalk among these pathways, in which cGAS-STING and NLRP3 reinforce inflammatory signaling, while NLRP3-driven TREM2 shedding may impair microglial clearance and perpetuate proteostatic failure. Understanding this immune network may help define disease subtypes, identify biomarkers, and guide combinatorial therapeutic strategies that suppress harmful inflammation while preserving protective microglial functions.

Indexed as

Amyotrophic lateral sclerosiscGAS-STINGFrontotemporal dementiaMicrogliaNeuroinflammationNLRP3 inflammasomeTREM2

Identifiers

PMID42359357
PMCPMC13292674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.